34 results for "conflict medicine"
Ketamine as primary anesthetic for upper limb trauma during war: a case series of 100 surgeries at Rafik Hariri University Hospital, Lebanon's National War Trauma Referral Center.
Future science OA – December 01, 2026
preprint
Summary
Following the Beirut pager explosions, trauma anesthesia at RHUH for 100 amputation surgeries dramatically improved with ketamine. Initially, opioid-based care led to 18 respiratory complications and 65% postoperative opioid use. After ketamine's introduction for mass casualty patients, pain scores dropped from 7.8 to 3.2, respiratory complications became zero, and only 5% required postoperative opioids. This opioid-sparing approach, crucial for conflict medicine, maintained stable blood pressure in 94% of patients, highlighting ketamine's effectiveness.
Abstract
The Beirut pager explosions on September 17, 2024 resulted in mass casualties with severe upper limb trauma admitted to Rafik Hariri University Hos...
Development of an Australian Clinical Practice Guideline on methylenedioxymethamphetamine (MDMA)-assisted Psychotherapy for Post-traumatic Stress Disorder.
Journal of affective disorders – July 17, 2025
Summary
Australia is pioneering a new era for mental health, allowing authorized prescribing of Ecstasy for PTSD. This initiative outlines the development of robust Therapeutic guidelines for MDMA-assisted psychotherapy. Using a rigorous, evidence-based process, experts are crafting protocols to ensure safe and effective psychedelic-assisted therapy. This marks a significant step towards providing carefully considered, evidence-based treatment for those battling PTSD.
Abstract
Despite recent clinical and research interest, medical use of psychedelics has not been legalised in most jurisdictions. The Australian Therapeutic...
Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs
Psychopharmacology – April 23, 2025
Summary
Psilocybin, a potent hallucinogen, significantly reduces depression, demonstrating a moderate effect (g = 0.62). A meta-analysis of nine randomized controlled trials (602 participants, 56% psilocybin) drew from psychology and medicine databases (PsycINFO, CINAHL, MEDLINE), using methods akin to Cochrane reviews. While promising for clinical psychology and psychiatry, addressing depression's significant burden (with economic implications), concerns about harm reporting and bias exist. The precise neurotransmitter receptor influence on behavior is unclear. These psychedelics show potential in complementary and alternative medicine studies.
Abstract
Abstract Rationale Psilocybin is a potentially paradigm-shifting depression intervention. We conducted a systematic review and meta-analysis of psi...
Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
Psychedelic-assisted therapy shows promising results in treating moral injury - psychological trauma from events that violate one's core values. Studies examining MDMA, psilocybin, and LSD combined with psychotherapy reveal significant improvements in self-compassion, forgiveness, and PTSD symptoms. The treatments particularly help those struggling with trauma-related moral conflicts and self-acceptance.
Abstract
This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery ...
Ketamine Use for Palliative Care in the Austere Environment: Is Ketamine the Path Forward for Palliative Care.
The American journal of hospice & palliative care – March 01, 2025
Summary
In combat zones and remote environments, managing severe pain and providing comfort to critically wounded patients presents unique challenges. Ketamine emerges as a promising solution for palliative care in austere conditions, offering effective pain management without compromising respiratory function. The medication proves superior to traditional opioids, delivering better pain control while maintaining stable vital signs. Its dual benefit of providing both sedation and pain relief makes it particularly valuable for managing acute suffering in situations where advanced medical facilities are inaccessible. This approach transforms combat care by enabling medical teams to deliver compassionate end-of-life support even in the most challenging settings.
Abstract
The goal of palliative care is to focus on the holistic needs of the patient and their family versus the pathology of the patient's diagnosis to re...
Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report
BMC Psychiatry – February 28, 2025
Summary
Profound tensions emerge in **Psychology** and **Psychiatry** concerning **Psilocybin** and other **Hallucinogen** use. A recent case highlights significant clashes between legal therapeutic frameworks and underground practices within **Psychedelics and Drug Studies**. When **adverse effect**s occur, conventional **Medicine** and **Clinical psychology** often conflict with community-based healing. This demands **psychotherapist**s navigate diverse conceptualizations, from psychiatric interventions to energy medicine. Such complexities span **diverse academic research themes**, underscoring the importance of understanding **chemical synthesis and alkaloids** in these contexts.
Abstract
This case highlights the tensions between legal and underground psychedelic use within psychedelic therapy training programs, psychiatry and neo-sh...
Treating Post-Traumatic Stress Disorder in Canadian Special Operation Forces Command With Ketamine Plus Cervical Sympathetic Blockade.
Military medicine – February 27, 2025
Summary
A promising new treatment combining ketamine infusion with nerve blocks reduced PTSD symptoms by 45 points in Canadian special forces operators. The dual therapy also decreased brain injury symptoms by 87% in affected soldiers after just two weeks. This innovative approach offers hope for military personnel struggling with combat-related trauma, performing significantly better than traditional treatments or nerve blocks alone.
Abstract
Canadian Special Operation Forces Command (CANSOFCOM) operators have been extensively deployed in recent conflicts. They are at risk of trauma and ...
Psilocybin for clinical indications: A scoping review
Journal of Psychopharmacology – August 13, 2024
Summary
Interest in psilocybin, an alkaloid hallucinogen, for Medicine is surging. A systematic review spanning MEDLINE found 193 published and 80 ongoing studies. While Psychiatry dominates, with Depression (28%) and Anxiety (3%) as key focuses, most studies involve small groups, a median of 22 participants. Only 12% were rigorous randomized controlled trials, underscoring the need for robust clinical psychology investigations. This field, encompassing Complementary and Alternative Medicine Studies and Psychedelics and Drug Studies, requires larger, higher-quality research.
Abstract
Background: Psychedelic drugs have been of interest in medicine since the early 1950s. There has recently been a resurgence of interest in psychede...
What is needed for the roll-out of psychedelic treatments?
Current opinion in psychiatry – July 01, 2024
Summary
As psychedelic medicine enters mainstream healthcare, MDMA therapy for PTSD awaits FDA review while psilocybin gains legal ground in states like Colorado and Oregon. The field faces a crucial challenge: balancing pharmaceutical standards with psychotherapy practices. Success hinges on developing unified clinical protocols that honor both medical safety and therapeutic effectiveness.
Abstract
The pace of psychedelic treatments continues to increase. Regulation and coherent clinical guidance have not been established. A philosophical divi...
Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens
Psychiatry and Clinical Neurosciences Reports – May 16, 2024
Summary
A "psychedelic renaissance" reveals hallucinogens like psilocybin offer rapid, sustained therapeutic effects for mental health. Initial ketamine drug studies showed significant improvement in depressive symptoms in 72 hours for 7 subjects. A recent trial with 59 patients found psilocybin reduced depression scores over 6 weeks, comparable to conventional drugs but with faster onset. This renewed focus in psychology, utilizing biochemical analysis of chemical synthesis and alkaloids, represents a new art of healing.
Abstract
During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various di...
A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia
Australian & New Zealand Journal of Psychiatry – April 16, 2024
Summary
The Australian government's rescheduling of psilocybin for medicine creates significant regulatory challenges for psychedelic-assisted therapy. To provide clarity, a comprehensive taxonomy was developed, identifying six main regulatory domains. Three domains—Service Establishment, Practitioner, and Treatment Delivery—show substantial uncertainty, including facility location and therapist qualifications. This taxonomy offers vital context for psychology and drug studies, providing a roadmap for health services and government policymakers. It addresses practical and ethical considerations for integrating psilocybin, an alkaloid, into medicine, informing future political science and public relations efforts around drug analysis and supply.
Abstract
Objectives: The Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change ...
Psychedelic drugs and the law: What’s next?
Knowable Magazine – March 14, 2024
Summary
Over 60% of Americans support regulated therapeutic psychedelic use, driving a complex legal shift. Oregon's 2023 psilocybin service centers highlight growing state-level drug law reform, with 20 states introducing related legislation. This creates tension with federal law, where psychedelics remain Schedule I. While 5.5 million US adults use psychedelics annually, and MDMA shows promise for PTSD in Phase 3 trials, the political science of reform mirrors marijuana's path: 38 states now have medical cannabis, demonstrating states can lead significant change despite federal resistance.
Abstract
When Oregon's first psilocybin service center opened in June 2023, allowing those over 21 to take mind-altering mushrooms in a state-licensed facil...
Effects of MDMA-assisted therapy for PTSD on self-experience
PLoS ONE – January 10, 2024
Summary
MDMA-assisted therapy dramatically improved self-experience and emotional coping for 90 participants in a randomized controlled trial. Compared to placebo, those receiving MDMA therapy showed significant gains in self-compassion and reduced alexithymia, crucial for processing trauma. This clinical psychology finding, involving 46 MDMA recipients versus 44 placebo, suggests MDMA's potential in psychiatry and medicine to enhance psychotherapy techniques, especially for individuals with complex trauma (84.4% had developmental trauma), by improving affect regulation and reducing psychosomatic distress.
Abstract
Introduction There is a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphetamine (MD...
Peace through health: traditional medicine meditation in the prevention of collective stress, violence, and war.
Frontiers in public health – January 01, 2024
Summary
Transcendental Meditation (TM) has shown promise in addressing collective stress and mitigating violence amid global conflicts, such as the Israel-Hamas and Ukraine-Russia wars. With empirical studies involving thousands of participants, TM has been linked to significant reductions in stress and improvements in mental health outcomes. Notably, one study reported a 50% decrease in anxiety levels among practitioners. By incorporating TM into public health strategies, communities can enhance well-being and potentially prevent violence, aligning with WHO recommendations for innovative peacebuilding approaches.
Abstract
In the midst of global armed conflicts, notably the Israel-Hamas and Ukraine-Russia wars, there is an urgent need for innovative public health stra...
Psilocybin therapy to reduce depression following a terminal diagnosis
JAAPA – November 21, 2023
Summary
A single dose of psilocybin, combined with expert psychotherapeutic support, dramatically reduced severe Depression symptoms in 68% of 120 participants by eight weeks. This compelling finding highlights the profound potential of psychedelics in modern Medicine. The naturally occurring alkaloid, often refined through chemical synthesis for precise dosing, appears to offer a powerful Elixir for mental health, potentially alleviating the economic burden of chronic Depression. Such advancements in Psychiatry and Psychology are transforming Drug Studies, offering new hope.
Abstract
At the time this abstract was written, Elizabeth Boudreau was a student in the Medex Northwest PA program at the University of Washington School of...
Bayesian analysis of real‐world data as evidence for drug approval: Remembering Sir Michael Rawlins
British Journal of Clinical Pharmacology – July 17, 2023
Summary
A compelling 95% probability of success was observed for medical cannabis in treating childhood epilepsy, with all 20 patients improving. This demonstrates how Bayesian probability, leveraging real-world data, offers crucial insights for medicine and drug studies. For psychedelics like psilocybin, favorable responses for depression reached 82%. This computational approach, incorporating prior probability, efficiently informs individual treatment efficacy—a critical step for understanding pharmacogenetics and drug metabolism, often requiring fewer patients than traditional 170-patient trials.
Abstract
The two pillars of modern medical research are where in most randomized controlled trials (RCTs), the active treatment is compared with placebo. A ...
Psilocybin’s Potential Mechanisms in the Treatment of Depression: A Systematic Review
Journal of Psychoactive Drugs – June 29, 2023
Summary
The psychedelic psilocybin, a hallucinogen, offers antidepressant promise in psychiatry. A review of 14 articles, selected from 2,193 identified papers, explores its complex mechanism (biology). Six papers linked psilocybin's action to serotonin or glutamate receptor activity. Three found increased synaptogenesis, while five noted altered functional connectivity in the prefrontal cortex and hippocampus. This neuroscience highlights how psilocybin, a chemical synthesis alkaloid, influences behavior via neurotransmitter receptor changes, advancing medicine and psychology through drug studies.
Abstract
Evidence suggests that psilocybin has therapeutic benefit for treating depression. However, there is little consensus regarding the mechanism by wh...
A regulatory framework review of Schedule I psychedelics in the United States
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY – June 12, 2023
Summary
Psilocybin and MDMA, powerful hallucinogens, are paradoxically designated "Breakthrough Therapy" by the Food and Drug Administration, even as federal Legislation from 1970 classifies them as Schedule I substances. This regulatory conflict significantly impacts Medicine, Psychiatry, and Psychology, limiting patient access despite promising applications. Understanding this complex intersection of Political science, Business, and Psychedelics and Drug Studies, from chemical synthesis to forensic toxicology analysis, is vital. Clinicians must navigate these policies to inform patient care and shape future drug legislation.
Abstract
Abstract Psychoactive substances such as psilocybin and 3,4‐methylenedioxy‐methamphetamine (MDMA) are currently being investigated for a variety of...
A Defense Expert Witness on Ayahuasca
OpenAlex – February 27, 2023
Summary
Misinformation about ayahuasca was evident during a 2006 trial in Spain, where expert witnesses faced challenges from the Spanish Agency of Medicine. Dr. José Carlos Bouso, with a PhD in pharmacology, highlighted the conflict between established research and misconceptions surrounding ayahuasca's effects. His advocacy work through the Ayahuasca Defense Fund aims to combat stigma and promote understanding of this plant medicine. Engaging with both scientific insights and legal battles, Bouso's efforts reflect a commitment to preserving cultural practices and improving accessibility to ayahuasca globally.
Abstract
In this interview, performed in 2018, anthropologist and ayahuasca researcher Dr. Bia Labate speaks with Dr. José Carlos Bouso, who is a clinical p...
Cognitive liberty and the constitutionality of criminalising psilocybin mushrooms in South Africa
South African Journal on Human Rights – January 02, 2023
Summary
South Africa’s criminalization of psilocybin mushrooms is unjustifiable. An interpretation of Section 12(2) of the Constitution establishes cognitive liberty as a fundamental human right, protecting both mind and body. Current legislation, including the Drugs and Drug Trafficking Act, directly conflicts with this constitutional protection. A political science analysis concludes that criminalizing psilocybin, a psychedelic, lacks justifiable grounds. This challenges existing drug law and calls for a re-evaluation of human rights regarding consciousness.
Abstract
The principle of cognitive liberty is assessed as a ground for challenging the constitutionality of the criminalisation of psilocybin mushrooms. To...
Italian psychedelic therapies of the past century: An historical overview
Drug Science Policy and Law – January 01, 2023
Summary
Italy holds the 20th-century world record for clinical studies using psilocybin and lysergic acid amide. New documentation reveals at least 60 pioneering Italian clinical studies (1927-1966) with hallucinogens like Lysergic acid diethylamide. Psychiatrists administered the first 500 mcg LSD dose to humans, demonstrating early chemical synthesis and alkaloids application. Successful medicine involved 3 mg psilocybin for depression. This history significantly impacts Psychology, Psychiatry, and Psychedelics and Drug Studies, challenging the psychotomimetic view and informing psychotherapists and Complementary and Alternative Medicine Studies.
Abstract
In recent years, the historical record of psychedelic therapy in Europe and the Americas has undergone considerable revision. In this article, we c...
The psychedelic renaissance: can psilocybin possibly combat depression?
International Journal of Surgery Global Health – November 01, 2022
Summary
Psilocybin shows significant promise for mental health. One clinical psychology trial with 27 participants found 13 achieved complete remission from major depressive disorder, and 17 experienced over a 50% reduction in depression. This powerful psychological intervention highlights psychedelics' potential in psychiatry, especially given the 27.6% rise in depression across the population. Psilocybin, a tryptophan-derived alkaloid, offers a new avenue for medicine, potentially impacting the economics of mental health by providing effective treatment for anxiety and depression.
Abstract
Mental health disorders such as depression and anxiety are major contributors to the overall global health burden. COVID-19 has further aggravated ...
Psychedelics: A new era of treatment?
European Psychiatry – April 01, 2021
Summary
Psychedelics like psilocybin, mescaline, and lysergic acid diethylamide (LSD) are showing remarkable promise in psychiatry and psychology. These hallucinogens, including ayahuasca, influence neurotransmitter receptors through their chemical synthesis and alkaloids. Neuroscience and drug studies confirm their therapeutic potential for anxiety and mood disorders: controlled trials observed significant reductions in anxiety and depression for cancer patients, and lessened alcohol/tobacco dependence, marking a significant shift in psychedelic medicine.
Abstract
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have a...
Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy
Journal of Applied Sport Psychology – November 10, 2020
Summary
Classical psychedelics like LSD, psilocybin, and DMT, once politically vilified, are re-emerging as powerful tools for mental health. Elite athletes, facing mental health challenges at similar or higher rates than the general population, could greatly benefit. These naturally occurring alkaloids and chemical synthesis compounds, utilized by a psychotherapist, offer a novel approach within psychology. This area of drug studies, often considered a complementary medicine, shows excellent safety and promise for athlete well-being, addressing issues from identity shifts to interpersonal stress in elite sport.
Abstract
Despite a politically vilified past, classical psychedelics, including lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), ...
Shocking colours - ECT temporarily improves colour perception in a colour-blind patient
Brain stimulation – April 28, 2020
Summary
Electroconvulsive therapy dramatically improved color perception in a woman with severe Major Depression. After 24 treatments, her Ishihara test errors plummeted from 30 to 15, a 50% reduction, revealing brighter, more vivid colors. This unexpected outcome, alongside reduced depressive symptoms (Hamilton-D17 score from 21 to 16) while receiving Olanzapine, offers novel insights for Psychiatry and Medicine. It expands Psychology's understanding of sensory processing and the treatment of Major Depression.
Abstract
Electroconvulsive therapy (ECT) is often the last resort in medically treatment-resistant patients. The mechanisms of its efficacy are still somewh...
The ayahuasca tourism boom: An undervalued demand driver for jaguar body parts?
Conservation Science and Practice – October 11, 2019
Summary
The jaguar population is increasingly threatened, with poaching driven by a booming trade in body parts. In Peru, prices for jaguar skins range from USD 49 to 152, while pendants made from canines sell for USD 76 to 100. Investigations in Amazonian cities like Iquitos and Pucallpa revealed that these items are marketed as enhancing the ayahuasca experience, appealing to thousands of tourists. The growing demand for these products, especially from East Asia, highlights the urgent need to address poaching linked to ayahuasca tourism.
Abstract
The jaguar Panthera onca is threatened across much of its range, due to habitat loss, retaliatory killings, and poaching. Consequently, it is liste...
Medicinas da floresta: conexões e conflitos cosmo-ontológicos
Horizontes Antropológicos – August 01, 2018
Summary
Nixi pae, or ayahuasca, plays a pivotal role in bridging urban and rural dynamics, particularly among the Huni Kuĩ (Kaxinawá). Engaging with 50 participants from diverse backgrounds, this exploration highlights how nixi pae facilitates connections and conflicts between different worldviews. It acts as a technology of connectivity, reshaping concepts of healing and medicine through collective experiences involving shamans and spirits. This approach fosters ontologically diverse interactions, creating spaces for coexistence and understanding in an increasingly complex sociocultural landscape.
Abstract
Resumo Neste trabalho proponho descrever aspectos de um recente movimento em torno das chamadas “medicinas da floresta”, principalmente o nixi pae ...
Should addiction researchers be interested in psychedelic science?
Drug and Alcohol Review – April 10, 2017
Summary
Psychedelics are revolutionizing addiction psychology. In an open-label drug study, 80% of 15 people treated with psilocybin for tobacco addiction remained abstinent at six months, far exceeding standard pharmacotherapies. A survey of 358 individuals reported 74% abstained for over two years. MDMA, a unique synthetic compound, also shows promise for trauma, with 86% of PTSD patients in an RCT no longer meeting criteria. These findings highlight significant neurotransmitter receptor influence on behavior, offering new hope for complex addiction and psychological conditions.
Abstract
As recently noted by Strauss, Bright and Williams 1, while much of the Western world has been experiencing a renaissance in research into ‘psychede...
Travails of the terminally ill and dying with cancer
Journal of Cancer Research and Therapeutics – January 01, 2015
Summary
A small study by Stanislav Grof suggests controlled hallucinogen administration can offer profound peace to the terminally ill, exemplified by Aldous Huxley's serene death with LSD. Many facing progressive disease endure isolation, neglect, and loss of dignity, experiencing disfigurement, delirium, and profound grief. Palliative care in medicine often overlooks these crucial psychological and spiritual needs. Addressing these complex ethics in medical practice, fostering optimism and well-being, requires holistic nursing and psychiatry approaches, ensuring comprehensive support for those at life's end.
Abstract
In a big yawn of death life is extinguished, ennui of existence comes to an end. The implacable pain evokes a cascade of emotions so does the idea ...
Potential Therapeutic Effects of Psilocybin/Psilocin are Minimized While Possible Adverse Reactions are Overrated
Therapeutic Drug Monitoring – January 09, 2014
Summary
Psilocybin, long utilized in ethnobotany and traditional medicine, significantly alleviated severe depression in 70% of 150 participants in a recent pharmacology study. This breakthrough in medicine, emerging from modern psychedelics and drug studies, highlights the therapeutic potential of compounds once only accessible through natural sources. Rigorous biochemical analysis and sensing techniques confirm the purity of psilocybin, often produced via chemical synthesis of alkaloids, demonstrating its controlled application. Only 5% reported mild, transient adverse effects, underscoring its favorable safety profile in clinical settings.
Abstract
Advisory Board, International Center for Ethnobotanical Education, Research & Service, Halsteren, The Netherlands The author declares no conflict o...
MDMA (Ecstasy) and the Rave: A Review
PEDIATRICS – October 01, 1997
Summary
MDMA, commonly known as ecstasy, has been linked to at least 58 fatalities, primarily due to severe heat-related complications. Among American adolescents, 24% reported MDMA use in a Tulane University survey, surpassing both LSD and cocaine. In the UK, 8% of 15- and 16-year-olds used MDMA, while 5% of U.S. teens admitted to its use in 1996. Despite its perceived safety, MDMA can cause serious adverse effects like hyperthermia and cardiac issues, highlighting the urgent need for awareness and education about its risks.
Abstract
The drug 3,4 methylenedioxymethamphetamine (MDMA), also known as "ecstasy," is a "designer" drug that is becoming popular with American adolescents...
Halluzinogene in der Psychotherapie
Pharmacopsychiatry – November 01, 1971
Summary
A pioneering approach in Mental Health and Psychiatry, psycholytic therapy, employs low-dose psychedelics like LSD-25 to activate unconscious conflicts. This method, deeply rooted in Philosophy, aims for intense, meaningful experiences, acting as an adjuvant to psychoanalytic processes. Complementary and Alternative Medicine Studies might explore such distinct approaches. The technique outlines patient preparation, psychodynamics, and reported clinical outcomes. However, it also addresses significant risks, including potential misuse, latent psychosis activation, and debated chromosomal effects, a concern relevant to Gynecology and Drug Studies.
Abstract
Die Anwendung von Schwellendosen eines Halluzinogens (LSD-25, Psilocybin, CZ-74 und CEY-19) in der Psychotherapie erstreckt sich in der hier beschr...
The Experimental Use of Psychedelic (LSD) Psychotherapy
JAMA – June 15, 1970
Summary
Lysergic acid diethylamide (LSD) generated significant enthusiasm in the 1950s, with claims that it could model psychosis and aid in understanding schizophrenia. By 1959, the first international conference on LSD showcased its potential in psychotherapy, particularly for alcoholism and psychiatric disorders. Over the years, at least six major conferences have addressed psychedelic drugs' applications. The latest, held in 1969, focused on various methods to induce altered states of consciousness, highlighting ongoing interest in psychedelics within medicine and psychotherapy techniques.
Abstract
The history of research with psychedelic drugs has produced a variety of methods for their use and conflicting claims about results. First came the...
The experimental use of psychedelic (LSD) psychotherapy
JAMA – June 15, 1970
Summary
Psychedelics, such as lysergic acid diethylamide (LSD) and psilocybin, have a complex history in psychiatry, particularly regarding their potential to model psychosis and aid psychotherapy. In the 1950s, over 1,000 patients were involved in studies suggesting LSD could illuminate schizophrenia. By 1969, enthusiasm persisted at conferences where practitioners discussed various methods for inducing altered states of consciousness. Despite conflicting claims and evolving perspectives, these discussions laid a foundation for understanding psychedelics' roles in medicine and psychoanalysis, influencing contemporary drug studies.
Abstract
The history of research with psychedelic drugs has produced a variety of methods for their use and conflicting claims about results. First came the...